A Phase II, Single Arm, Open-label, Multicenter, Study of Oral LGX818 in Patients With BRAF V600 Mutant, Advanced Non-small Cell Lung Cancer (NSCLC) That Have Progressed During or After at Least One Prior Chemotherapy
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 17 Feb 2016
Price : $35 *
At a glance
- Drugs Encorafenib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Array BioPharma; Novartis Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 11 Jan 2016 Status changed from suspended to withdrawn prior to enrolment as per ClinicalTrials.gov record.
- 20 Jun 2014 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov record.